Monitor for immediate selling by insiders (Ting Yang, Lina Deng, David Lazar) which could pressure the stock. The company's lack of pipeline and going-concern status make further dilutive financing or a distressed sale likely. Traders should watch for any 8-K filings regarding strategic alternatives or additional capital raises.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 29 $3.06entry
- T+1 · 5mo ago −1.96%α −2.74% · $3.00
- T+5 · 4mo ago −6.86%α −8.25% · $2.85
- T+20 · 4mo ago −14.71%α −14.43% · $2.61
- T+60 · 8w ago +30.39%α +26.01% · $3.99
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Indaptus Therapeutics filed an S-3 registration statement to allow selling stockholders (Ting Yang, Lina Deng, and David Lazar) to resell up to 18,864,000 shares of common stock, representing approximately 14.2% of outstanding shares. The company will not receive any proceeds. This filing comes amid a severe operational crisis: the company has discontinued all clinical development of its lead candidate Decoy20, has no active programs, and its auditor has expressed substantial doubt about its ability to continue as a going concern. The resale registration creates significant overhang and facilitates insider selling, compounding the fundamental distress.
Key Facts
- 18,864,000 shares registered for resale by three selling stockholders (Ting Yang, Lina Deng, David Lazar), approximately 14.2% of the 133,242,324 shares outstanding.
- Company receives no proceeds; all proceeds go to selling stockholders.
- Decoy20 clinical programs fully discontinued; no active clinical development programs.
- Auditor's report includes a going-concern explanatory paragraph.
- Change of control occurred in March 2026; new management and board in place.
- Multiple dilutive financings in the past 18 months: June 2026 private placement ($12M), June 2025 private placement ($2.3M convertible notes), and various other offerings.
Financial Impact
Potential overhang of ~14.2% of outstanding shares; at the June 22, 2026 closing price of $3.775, the registered shares have a market value of approximately $71.2 million.
Risk Factors
- Insider selling from the registered shares could create sustained downward pressure.
- Company may need to raise additional capital at distressed terms, further diluting existing shareholders.
- Inability to secure a strategic transaction or financing could lead to delisting or bankruptcy.
- Concentrated ownership (96.2% held by a small group after March 2026 transfer) creates governance and liquidity risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001493152-26-030346 |
| Exhibit: ex107.htm | 0001493152-26-030346 |
| Exhibit: ex5-1.htm | 0001493152-26-030346 |
| Exhibit: ex23-2.htm | 0001493152-26-030346 |
| Document: 0001493152-26-030346-index-headers.html | 0001493152-26-030346 |
| Document: 0001493152-26-030346-index.html | 0001493152-26-030346 |
| Document: 0001493152-26-030346.txt | 0001493152-26-030346 |
Track record
20 reports on INDP
3 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +59.35% at T+20 after the Jul 20, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $3.17 Now $3.45 +8.83% settles Dec 15
- Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
- Oct 22, 202625d ago SC 13D/A Neutral 3/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
- Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
- Oct 21, 202626d ago SC 13D/A Neutral 4/10 Entry $2.99 Now $3.45 +15.38% settles Nov 19
- Oct 20, 202627d ago 8-K Bearish 6/10 Entry $3.16 Now $3.45 −9.18% settles Nov 18
- Sep 30, 20266w ago 8-K Neutral 3/10 Entry $2.30 to $3.31 Now $3.45 +50.00% ▲ +43.70% +42.43% vs SPY
- Sep 9, 20269w ago 8-K Bearish 7/10 Entry $2.56 to $2.37 Now $3.45 −34.77% ▲ +7.42% +9.55% vs SPY
- Sep 4, 202610w ago 424B5 Bearish 6/10 Entry $1.85 to $2.59 Now $3.45 −86.49% ▼ −40.00% −38.29% vs SPY
- Sep 1, 202610w ago 8-K Bearish 5/10 Entry $1.13 to $2.32 Now $3.45 −205.31% ▼ −104.87% −103.69% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers